Literature DB >> 8847404

Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys.

D M Gash1, Z Zhang, W A Cass, A Ovadia, L Simmerman, D Martin, D Russell, F Collins, B J Hoffer, G A Gerhardt.   

Abstract

Effects of a single injection of either 150 micrograms human recombinant glial cell line-derived neurotrophic factor (rGDNF) or vehicle into the right substantia nigra were analyzed in 12 normal adult female rhesus monkeys. The studies included evaluating whole animal behavior, electrochemical recordings of striatal dopamine release, neurochemical determinations of basal ganglia and nigral monoamine levels, and immunohistochemical staining of the nigrostriatal dopamine system. The behavioral effects over the 3-week observation period following trophic factor administration were small, with blinded observers unable to distinguish between GDNF- and vehicle-treated animals. Quantitative measurements did show that five of six trophic factor recipients experienced some weight loss and four of the six GDNF recipients displayed small, but significant, increases in daytime activity levels. In vivo electrochemical recordings in the ipsilateral caudate and putamen 3 weeks after GDNF administration revealed increased potassium-evoked release of dopamine in trophic factor recipients. In a second series of animals killed at the same time, dopamine levels in the substantia nigra and ventral tegmental area of GDNF recipients were significantly increased, with ipsilateral values more than 200% higher than contralateral and control levels. Levels of the dopamine metabolite HVA were significantly elevated in the substantia nigra, ventral tegmental area, and caudate nucleus ipsilateral to the trophic factor injection. There was a trend toward increased HVA levels in the ipsilateral putamen, nucleus accumbens, and globus pallidus in GDNF-treated animals, but the ratios of HVA to dopamine were not significantly different between vehicle- and GDNF-treated recipients. Although some tissue damage from the delivery of concentrated trophic factor was evident, dopamine neurons remained in an adjacent to the injection site. In the substantia nigra ipsilateral to GDNF administration, dopamine-neuron perikaryal size was significantly increased, along with a significant increase in tyrosine hydroxylase-positive axons and dendrites. We conclude that, in the adult rhesus monkey, a single intranigral GDNF injection induces a significant upregulation of mesencephalic dopamine neurons which lasts for weeks.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8847404     DOI: 10.1002/cne.903630302

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  20 in total

1.  GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis.

Authors:  C M Kearns; W A Cass; K Smoot; R Kryscio; D M Gash
Journal:  J Neurosci       Date:  1997-09-15       Impact factor: 6.167

Review 2.  Neurotoxins as Preclinical Models for Parkinson's Disease.

Authors:  Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2018-01-08       Impact factor: 3.911

3.  Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine.

Authors:  Michael P Smith; Anita Fletcher-Turner; David M Yurek; Wayne A Cass
Journal:  Neurochem Res       Date:  2006-04       Impact factor: 3.996

4.  Cortical glutamate levels decrease in a non-human primate model of dopamine deficiency.

Authors:  Z Zhang; J E Quintero; X T Fan; F Zhao; Y Ai; A Andersen; P Hardy; F Ling; G A Gerhardt
Journal:  Brain Res       Date:  2014-01-04       Impact factor: 3.252

5.  Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.

Authors:  Mei Sun; Lingxin Kong; Xiaodan Wang; Xiu-gui Lu; Qingsheng Gao; Alfred I Geller
Journal:  Brain Res       Date:  2005-08-09       Impact factor: 3.252

6.  Globus pallidus plays a critical role in neurotrophic factor induced functional improvements in hemiparkinsonian monkeys.

Authors:  Tao Xin; Yi Ai; Greg Gerhardt; Don Gash; Zhiming Zhang
Journal:  Biochem Biophys Res Commun       Date:  2008-03-31       Impact factor: 3.575

7.  Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity.

Authors:  Fredric P Manfredsson; Nihal Tumer; Benedek Erdos; Tessa Landa; Christopher S Broxson; Layla F Sullivan; Aaron C Rising; Kevin D Foust; Yi Zhang; Nicholas Muzyczka; Oleg S Gorbatyuk; Philip J Scarpace; Ronald J Mandel
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

8.  GDNF protection against 6-OHDA-induced reductions in potassium-evoked overflow of striatal dopamine.

Authors:  W A Cass; M W Manning
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

Review 9.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

10.  Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration.

Authors:  Kevin Gregory-Evans; Francis Chang; Matthew D Hodges; Cheryl Y Gregory-Evans
Journal:  Mol Vis       Date:  2009-05-13       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.